Dosing of BRAF and MEK inhibitors in melanoma: no point in taking a break

Jenny H. Lee; Matteo S. Carlino; Helen Rizos

doi:10.1016/j.ccell.2020.11.010

Dosing of BRAF and MEK inhibitors in melanoma: no point in taking a break

Jenny H. Lee, Matteo S. Carlino, Helen Rizos^*

^*Corresponding author for this work

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAF^V600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAF^V600-mutant melanoma patients.

Original language	English
Pages (from-to)	779-781
Number of pages	3
Journal	Cancer Cell
Volume	38
Issue number	6
DOIs	https://doi.org/10.1016/j.ccell.2020.11.010
Publication status	Published - 14 Dec 2020

Access to Document

10.1016/j.ccell.2020.11.010

Cite this

@article{9785bc76cc0041e4922b7fb89c69fcbb,

title = "Dosing of BRAF and MEK inhibitors in melanoma: no point in taking a break",

abstract = "Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAFV600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAFV600-mutant melanoma patients.",

author = "Lee, {Jenny H.} and Carlino, {Matteo S.} and Helen Rizos",

year = "2020",

month = dec,

day = "14",

doi = "10.1016/j.ccell.2020.11.010",

language = "English",

volume = "38",

pages = "779--781",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Dosing of BRAF and MEK inhibitors in melanoma

T2 - no point in taking a break

AU - Lee, Jenny H.

AU - Carlino, Matteo S.

AU - Rizos, Helen

PY - 2020/12/14

Y1 - 2020/12/14

N2 - Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAFV600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAFV600-mutant melanoma patients.

AB - Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAFV600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAFV600-mutant melanoma patients.

UR - http://www.scopus.com/inward/record.url?scp=85097471320&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.11.010

DO - 10.1016/j.ccell.2020.11.010

M3 - Article

C2 - 33321086

AN - SCOPUS:85097471320

VL - 38

SP - 779

EP - 781

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -

Dosing of BRAF and MEK inhibitors in melanoma: no point in taking a break

Abstract

Access to Document

Other files and links

Fingerprint

Cite this